Abstract
Purpose
To quantify the importance of drug–drug interactions (DDIs) in the occurrence of adverse drug reactions (ADRs) reported with serotoninergic reuptake inhibitors in a pharmacovigilance database.
Methods
All spontaneous reports of ADRs registered in 2008 by the Midi-Pyrénées PharmacoVigilance Centre that contained mention of one of the serotoninergic reuptake inhibitor (SRI) antidepressants marketed in France were reviewed. DDIs were identified according to the French National Drug Formulary (Vidal) and the interaction supplement of the French independent drug bulletin La Revue Prescrire. ADRs explained by DDIs were characterised.
Results
Among the 2,101 spontaneous reports recorded, 177 involved at least one SRI antidepressant. Among the 156 ADRs with at least one theoretical DDI, 41% (95% confidence interval 34–49%) could be explained by a DDI. The most frequent antidepressant involved in DDIs was escitalopram, followed by fluoxetine and citalopram. Among the 65 ADRs related to DDIs, 37 (52.9%) were “serious”, mainly bleedings, confusion and falls, hyponatremia and serotoninergic syndromes. The most frequent drug interactions occurred with psychotropics (antipsychotics, benzodiazepines, among others), followed by antithrombotic agents (antagonists of vitamin K, antiplatelets), diuretics and angiotensin II antagonists. The group with ADRs related to DDIs was older than the group with ADRs not related to DDIs. ADRs were threefold more “serious” in the case of DDIs.
Conclusion
Around 40% of ADRs reported with SRIs were related to DDIs. Most of these occurred after association with psychotropics, antithrombotics, or diuretics, especially in the elderly.
Similar content being viewed by others
References
Baldessarini RJ (2006) Drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 429–459
Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221
Rédaction P (2011) Eviter les effets indésirables par interactions medicamenteuses: comprendre et décider. Rev Prescr 31:416
Lewis LD (2010) Drug–drug interactions: is there an optimal way to study them? Br J Clin Pharmacol 70:781–783
Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22:127–140
Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montastruc JL (2007) Drug interactions with Cholinesterase inhibitors: an analysis of the French PharmacoVigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 30:1063–1071
Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL (1995) French pharmacovigilance database system: examples of utilization. Thérapie 50:557–562
Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis and management. Lancet 356:1255–1259
Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory authorities. Drug Saf 2:109–117
Dictionnaire (2010) VIDAL, 86th edn. OVP, Paris
Gony M, Lapeyre-Mestre M, Montastruc JL (2003) Risk of serious extrapyramidal symptoms in patients with Parkinson’s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 26:142–145
Guitton E, Montastruc JL (2006) Lapeyre-Mestre M and the French Network of PharmacoVigilance Centers: influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 62:243–249
Berthet S, Grolleau S, Brefel-Courbon C, Montastruc JL, Lapeyre-Mestre M (2007) Prevalence of diabetes in France and drug use: study based on the French PharmacoVigilance database. Thérapie 62:483–488
Fletcher CV (2010) Drug interactions should be evaluated in patients. Clin Pharmacol Ther 88:5857
Ereshefsky L, Riesenman C, Lam YW (1995) Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 29[Suppl 1]:10–18
Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 33:454–471
Spina E, Scordo MG (2002) Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19:299–320
Spina E, Santoro V, D’Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206–1227
Remy N, Lapeyre-Mestre M, Bareille MP, Bagheri H, Montastruc JL (2000) Drug interactions: a prospective study in primary health care. Thérapie 55:395–398
Moore N, Le Cointre D, Noblet C, Mabille M (1998) Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45:301–308
Ghandi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556–1564
Spigset O (1999) Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 20:277–287
Wasserfallen JB, Livio F, Buclin T, Tillet L, Yersin B, Biollaz J (2001) Rate, type and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 12:442–447
Pirmohamed M, James S, Meakin S, Green C, Scot AK, Walley TL, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 329:15–19
Leone R, Magro L, Moreti L, Cutrneo P, Moschini M, Motola D, Tuccori M, Conforti A (2010) Identifying adverse drug reactions associated with drug-drug interactions. Drug Saf 33:667–675
Layton D, Clark DW, Pearce GL, Shakir SA (2001) Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleedings? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 57:167–176
Dalton SO, Sorensen HT, Johansen C (2006) SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 20:143–151
Douglas I, Smeeth L, Irvine D (2011) The use of antidepressants and the risk of stroke: a nested case control study. Br J Clin Pharmacol 71:116–120
Competing interests
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Contributions
F.M. and J-L.M performed the study in the French National PharmacoVigilance database. F.M and A.S analysed the data. J-L.M wrote the manuscript. E.B-G, G.D, H.B reviewed all the reports of ADRs. All of the authors revised the text.
Rights and permissions
About this article
Cite this article
Montastruc, F., Sommet, A., Bondon-Guitton, E. et al. The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol 68, 767–775 (2012). https://doi.org/10.1007/s00228-011-1156-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1156-7